Novo Seeks To Halt Caraco Launch Of Generic Prandin

Law360 (February 26, 2009, 12:00 AM EST) -- Novo Nordisk Inc. has asked a federal court to stop Caraco Pharmaceutical Laboratories Ltd. and its majority shareholder Sun Pharmaceutical Industries Ltd. from launching a generic version of Novo's diabetic drug Prandin before Novo has a chance to present its patent infringement case at trial.

In a motion for a preliminary injunction filed Wednesday in the U.S. District Court for the Eastern District of Michigan, Novo requested that the court temporarily prevent the defendants from launching “at-risk” their generic version of repaglinide, which Novo said all...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.